Covington brings a creative approach to our clients’ most sensitive and complex issues.  The San Francisco office combines the expertise and resources of a leading international law firm with a deep knowledge of key local industries.  Our client roster ranges from start-ups to Fortune 500 companies.  While much of our work focuses on the life sciences, financial services, and  technology and digital media sectors, we represent clients from a range of industries on a local, regional and global basis.

Our corporate practice concentrates on mergers and acquisitions, finance, venture capital and emerging companies, joint ventures and strategic collaborations, and licensing transactions in the biopharmaceutical, financial services, technology and media & entertainment industries. Our corporate attorneys represent major national and multinational pharmaceutical companies as well as a wide array of biotechnology, diagnostic and medical device companies, ranging from start-up ventures to industry leaders.  They also represent multimedia companies and artists in negotiating a wide range of agreements including licensing and distribution deals and advise clients on internet-related activities including e-commerce, blogging, and digital rights management strategies. 

The litigation practice emphasizes antitrust and consumer class action litigation, intellectual property litigation, financial and securities litigation, and insurance coverage litigation.  The San Francisco litigation practice has deep trial experience and has represented clients before the California Court of Appeals, the U.S. Court of Appeals for the Ninth Circuit, the Antitrust Division of the Department of Justice, the Federal Trade Commission, the Supreme Court and the European Union’s Directorate General for Competition.

In the News

Covington Advises J&J on Ethicon’s $785M Acquisition of Acclarent
12/17/2009

Covington Advises OVP Venture Partners on Fate Therapeutics Financing
11/16/2009

Covington Advises Boehringer Ingelheim on Acquisition of Animal Health Assets from Pfizer and Wyeth
9/24/2009